- Abramson A, Halperin F, Kim J, Traverso G. Quantifying the value of orally delivered biologic therapies: A cost-effectiveness analysis of oral semaglutide. Journal of pharmaceutical sciences. 2019.
- Hua LH, Hersh CM, Morten P, Kusel J, Lin F, Cave J, et al. The Impact of Price Reductions After Loss of Exclusivity in a Cost-Effectiveness Analysis: Fingolimod Versus Interferon Beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis. Journal of managed care & specialty pharmacy. 2019;25(4):490-8.
- Tubeuf S, Saloniki EC, Cottrell D. Parental Health Spillover in Cost-Effectiveness Analysis: Evidence from Self-Harming Adolescents in England. PharmacoEconomics. 2019;37(4):513-30.
HEDS is part of the School of Health and Related Research (ScHARR) at the University of Sheffield. We undertake research, teaching, training and consultancy on all aspects of health related decision science, with a particular emphasis on health economics, HTA and evidence synthesis.
Wednesday, 29 May 2019
April’s CEAs.....
We’ve completed our quick search for CEA’s published last month. In the right-hand column of this blog is a CEA Archive of all records. Below are those in our areas of interest.